RE:RE:RE:Interim Datas and speculationsGeeezwhizzz hope not.
I truly think that Adlai was limited to breast. Otherwise, management made a huge mistake of not limiting it.
from oncy's website:
We are working with Adlai Nortye, a biopharmaceutical company focused on discovering and developing important new treatments for cancer and metabolic diseases, to advance our phase 3 registration program in mBC and to leverage their distinct experience and expertise in drug development and commercialization in China, Hong Kong, Macau, Singapore, South Korea and Taiwan. Under the terms of the agreement, Adlai Nortye has exclusive development and commercialization rights to pelareorep for all indications in these territories.